Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 4, 2011, Pages 447-454

  Holzhäuser, Eva ^a   Albrecht, Claudia ^a   Zhou, Qianxing ^a   Buttler, Annette ^a   Preusch, Michael R ^a   Blessing, Erwin ^a   Katus, Hugo A ^a   Bea, Florian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apo E deficient mice; atherosclerosis; innominate artery; nicotinic acid; vascular inflammation; VCAM 1

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; THROMBOPLASTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIATHEROGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BRACHIOCEPHALIC TRUNK; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; IMMUNOHISTOCHEMISTRY; LIPOPROTEIN DEFICIENCY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THORACIC AORTA; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA, THORACIC; APOLIPOPROTEINS E; BRACHIOCEPHALIC TRUNK; FEMALE; INFLAMMATION; LIPIDS; MACROPHAGES; MICE; MICE, KNOCKOUT; NIACIN; PLAQUE, ATHEROSCLEROTIC; POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79954995814     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31820dc1db     Document Type: Article

References (50)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-1757. (Pubitemid 43767064)
2. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
3. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004; 363:757-767.
4. Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004;5:81-87.
5. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill, 2006;933-966.
6. Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol. 2010;30:151-155.
7. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. JIntern Med. 2008;263:256-273. (Pubitemid 351207349)
8. Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370-378. (Pubitemid 351787103)
9. Sviridov D, Mukhamedova N, Remaley AT, et al. Antiatherogenic functionality of high density lipoprotein: how much versus how good. JAtheroscler Thromb. 2008;15:52-62.
10. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15. (Pubitemid 19043669)
11. Gille A, Bodor ET, Ahmed K, et al. Nicotinic acid: pharmacological effects andmechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48: 79-106. (Pubitemid 351738150)
12. Digby JE, Lee JMS, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol. 2009;20:321-326.
13. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. JAm Coll Cardiol. 1986;8:1245-1255. (Pubitemid 17208898)
14. Brown BG, Zhao X, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592. (Pubitemid 33126837)
15. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353-361.
16. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009;202:68-75.
17. Wu BJ, Yan L, Charlton F, et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30: 968-975.
18. Warnholtz A, Wild P, Ostad MA, et al. Effects oforal niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study Atherosclerosis. 2009;204:216-221.
19. Hernandez M, Wright SD, Cai T. Critical role ofcholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun. 2007;355:1075-1080. (Pubitemid 46389506)
20. van der Hoorn JWA, de Haan W, Berbée JFP, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol. 2008;28:2016-2022.
21. DeclercqV, Yeganeh B, Moshtaghi-Kashanian G, et al. Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice. J Cardiovasc Pharmacol. 2005;46:18-24. (Pubitemid 40917774)
22. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
23. Moons AHM, Levi M, Peters RJG Tissue factor and coronary artery disease. Cardiovasc Res. 2002;53:313-325. (Pubitemid 34117681)
24. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517. (Pubitemid 39612564)
25. Phan BAP, Chu B, Polissar N, et al. Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging. Int J Cardiovasc Imaging. 2007;23: 337-342. (Pubitemid 46767508)
26. Lee JMS, Robson MD, Yu L, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787-1794.
27. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atheroscle-rosis. Atherosclerosis. 2003;170:191-203.
28. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. (Pubitemid 36019640)
29. Dansky HM, Barlow CB, Lominska C, et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb VascBiol. 2001;21:1662-1667. (Pubitemid 34215588)
30. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107:1255-1262. (Pubitemid 32494542)
31. Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res. 1999;85:199-207. (Pubitemid 29343319)
32. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2292-2301. (Pubitemid 350203942)
33. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114:1504-1511. (Pubitemid 44527006)
34. Chesney CM, Elam MB, Herd JA, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J. 2000;140:631-636.
35. Brown SL, Sobel BE, Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis. Circulation. 1995;92:767-772.
36. Tavintharan S, Sivakumar M, Lim S, et al. Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells. Clin Chim Acta. 2007;376:41-44. (Pubitemid 44880978)
37. Versteeg HH. Tissue factor as an evolutionary conserved cytokine receptor: implications for inflammation and signal transduction. Semin Hematol. 2004;41(1 suppl 1):168-172. (Pubitemid 38182734)
38. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atheroscle-rotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565-1569.
39. Thiruvikraman SV Guha A, Roboz J, et al. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest. 1996;75:451-461. (Pubitemid 26346797)
40. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003;303: 364-369. (Pubitemid 36338250)
41. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9:352.
42. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278: 9869-9874. (Pubitemid 36800490)
43. Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J InvestDermatol. 2006;126:2637-2646. (Pubitemid 44764048)
44. Kostylina G, Simon D, Fey MF, et al. Neutrophil apoptosis mediated by nicotinicacidreceptors(GPR109A). CellDeathDiffer. 2008;15:134-142.
45. Coppola A, Brady PG, Nord HJ. Niacin-induced hepatotoxicity: unusual presentations. South Med J. 1994;87:30-32. (Pubitemid 24044287)
46. Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA. 1990; 264:241-243. (Pubitemid 20212586)
47. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am JMed. 1992;93:102-104.
48. Lawrence SP. Transient focal hepatic defects related to sustained-release niacin.JClin Gastroenterol. 1993;16:234-236. (Pubitemid 23106893)
49. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study Am JCardiol. 1998; 82:U74-U81; Discussion U85-U86.
50. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. 2003;91:667-672. (Pubitemid 36287455)